• Monday, July 1, 2019 @ 9:00 am

BioVersys is strengthening its executive management team with the appointment of Dr. Stefano Biondi as Head of CMC as of July 1st, 2019. He will lead all CMC, contract manufacturing and supply chain activities in support of BioVersys’ preclinical and clinical development activities. Stefano is a pharmaceutical leader and innovator, with 30 years of R&D experience.


Stefano joins BioVersys from Allecra Therapeutics SAS where he was a founding member and Head of Preclinical Development, responsible for all non-clinical activities, CMC, supply chain and contract manufacturing for their lead antibiotic in Phase III clinical development. Prior to that, Stefano spent 12 years at GlaxoSmithKline leading medicinal chemistry teams in antibacterial research, before holding leadership positions in biotech companies such as Neuro 3D, NicOx and Allecra.


Dr. Marc Gitzinger, CEO and co-founder of BioVersys: “We are very pleased that Stefano is joining BioVersys during this important stage of rapid development in our company. We are now moving our candidate molecules through late stage preclinical development and preparing to enter clinical development in H1 2020. Stefano’s extensive R&D and CMC experience will be a strong asset to the company going forward”.


Dr. Stefano Biondi comments: “I am excited to join BioVersys, a leading European AMR biotech with a diverse pipeline of traditional and non-traditional antibiotics- BioVersys has a number of preclinical assets at different stages, two of which will enter human clinical studies shortly and I am looking forward to working with the experienced BioVersys team and contributing to the development and sucessful delivery of this unique pipeline.


Dr. Seng Chin Mah, Chairman of BioVersys: “BioVersys continues its progression towards being a clinical development company by strengthening the management team. The addition of Dr. Stefano Biondi, brings critical CMC and formulation experience to the team. We look forward to the BioVersys team advancing our assets to clinical development and addressing some serious unmet medical needs in the field of AMR as quickly as possible.”

You may also be interested in